您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (9): 77-80.doi: 10.6040/j.issn.1671-7554.0.2014.400

• 临床医学 • 上一篇    下一篇

乳腺癌患者血浆D-二聚体水平与预后关系的探讨

李玲1, 王丽丽2, 王胜江2, 于超2, 刘延鹏2, 徐成伟2   

  1. 1. 山东省肿瘤医院外科, 山东 济南 250117;
    2. 山东大学第二医院检验科, 山东 济南 250033
  • 收稿日期:2014-06-16 修回日期:2014-09-04 出版日期:2014-09-10 发布日期:2014-09-10
  • 基金资助:
    济南市高校自主创新计划(201303048)

Research on the relationship between plasma D-dimer level and prognosis of breast cancer

LI Ling1, WANG Lili2, WANG Shengjiang2, YU Chao2, LIU Yanpeng2, XU Chengwei2   

  1. 1. Department of Surgery, Shandong Provincial Tumor Hospital, Jinan 250117, Shandong, China;
    2. Department of Laboratory Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2014-06-16 Revised:2014-09-04 Online:2014-09-10 Published:2014-09-10
  • Contact: 徐成伟。E-mail:xuchengwei-jyk@163.com E-mail:xuchengwei-jyk@163.com

PDF (PC)

355

摘要： 目的 分析乳腺癌患者血浆D-二聚体水平的变化，探讨其与乳腺癌患者预后的关系。方法 收集原发性乳腺癌患者92例（病例组）和健康体检者85例（正常对照组），采用胶乳增强免疫比浊法测定血浆中D-二聚体水平，同时采用免疫组化法检测ER、PR、HER2、Ki-67和P53的表达；随访8个月，观察患者生存情况。分析根据不同指标分组的乳腺癌患者血浆D-二聚体水平的变化。结果 病例组与正常对照组相比血浆D-二聚体水平显著升高（P<0.01）；随访期间生存者血浆D-二聚体水平显著低于死亡者（P<0.05）；不同ER、PR、HER2、Ki-67和P53表达的乳腺癌患者间血浆D-二聚体水平无明显差异（P>0.05）。结论 D-二聚体可作为评价乳腺癌预后的指标，能够预测乳腺癌患者生存状况，而与激素受体等免疫组化指标无关。

关键词: 乳腺癌, 预后, 免疫组化, D-二聚体

Abstract: Objective To analyze the changes of plasma D-dimer level in breast cancer patients, and to investigate the relationship between the level of D-dimer and prognosis of breast cancer. Methods A total of 92 cases of primary breast cancer and 85 healthy controls were enrolled. The level of D-dimer was measured with latex-enhanced immunoassay, and ER, PR, HER2, Ki-67 and P53 levels were detected with immunohistochemical methods. During the follow-up of 8 months, the plasma D-dimer levels in breast cancer patients were analyzed. Results The level of D-dimer in breast cancer patients was significantly higher compared to that of the healthy controls (P<0.01); the level of D-dimer in survivors during follow-up was significantly lower than that in those who died (P<0.05); the level of plasma D-dimer in breast cancer patients with different expressions of ER, PR, HER2, Ki-67 and P53 showed no significant difference (P>0.05). Conclusion D-dimer can act as a predictor of breast cancer prognosis, while it has nothing to do with other immunohistochemical indexes.

Key words: Breast cancer, D-dimer, Prognosis, Immunohistochemistry

中图分类号: 

  • R737.9
[1] Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects[J]. Journal of Thrombosis and Haemostasis, 2013, 11(2): 223-233.
[2] Zacharski L R, Ornstein D L. Venous thromboembolism and cancer[J]. N Eng J Med, 2000, 343(5): 1338-47.
[3] Dirix L Y, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002, 86(11): 389-395.
[4] Benoy I H, Salgado R, Elst H, et al. Relative microve-ssel area of the primary tumour, and not lymph node sta-tus, predicts the presence of bone marrow micrometasta-ses detected by reverse transcriptase polymerase chain re-action in patients with clinically non-metastatic breast cancer[J]. Breast Cancer Res, 2005, 7(2): 210-219.
[5] Kono T, Ohtsuki T, Hosomi N, et al. Clinical character-istics of ischemic stroke in elderly patients with cancer[J]. Nihon Ronen Igakai Zasshi, 2011, 48(1): 57-62.
[6] 王丽丽, 徐成伟. 恶性肿瘤血栓形成机制研究进展[J]. 血栓与止血学杂志, 2013, 19(5): 237-240. WANG Lili, XU Chengwei. Advances of Study on Thrombosis in Malignant Tumor[J]. Chinese Journal of Thrombosis and Haemostasis, 2013, 19 (5): 237-240.
[7] 王胜江, 徐成伟. 血浆中凝血酶激活的纤溶抑制物(TAFI)水平与慢性肝损伤相关性研究[J]. 山东大学学报: 医学版, 2012, 50(4): 83-86. WANG Shengjiang, XU Chengwei. Circulating levels of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) in patients with chronic liver disease[J]. Journal of Shan-dong University: Health Sciences, 2012, 50(4): 83-86.
[8] Batschauer A P, Figueiredo C P, Bueno E C, et al. D-di-mer as a possible prognostic marker of operable hormone receptor-negative breast cancer[J]. Ann Oncol, 2010, 21(6): 1267-1272.
[9] Ay C I, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients[J]. Haematologica, 2012, 97(8): 1158-1164.
[10] Carey L A, Dees E C, Sawyer L, et al. The triple nega-tive paradox: primary tumor chemosensitivity of breast cancer sub-types[J]. Clin Cancer Res, 2007,13 (8): 2329-2334.
[11] Dent R, Trudeau M, Pritchard K I, et al. Triple-nega-tive breast cancer: clinical features and patterns of recur-rence[J].Clin Cancer Res, 2007, 13(15): 4449-4434.
[12] Kausch I, Lingnau A, Endl E et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo[J]. Int J Cancer, 2003, 105(12): 710-716.
[13] Rosa F E, Cladeira J R, Felipes J, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic fac-tors and proliferative marker Ki-67 in breast cancers[J]. Hum Pathol, 2008, 39(5): 720-730.
[14] Versteeg H H, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth[J]. Blood, 2008, 111(1): 190-199.
[15] Warnberg F, Nordgren H, Bergkvist L, et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness[J]. Br J Cancer, 2001, 85(6): 869-874.
[16] Choi H K, Roh S H, Kim H G, et al. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells[J]. Endocr Relat Cancer, 2008, 15(1): 139-147.
[17] Dent R, Trudeau M, Pritchard K I, et al. Prognostic markers in Triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
[1] 古春青,郭睿思,周勤勤,刘恒辉,巴婉玉,孙士玲,王冰,郑玉玲,吴宿慧. 基于网络药理学和动物实验探讨酸枣仁-远志药对治疗乳腺癌相关性失眠的作用机制[J]. 山东大学学报 (医学版), 2026, 64(1): 99-108.
[2] 李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[3] 刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[4] 王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[5] 王雪梅,杨豪,宋洋,程世超,张婷婷,王艳春. 抗糖尿病药物与女性恶性肿瘤的因果关联:一项两样本孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(6): 67-77.
[6] 贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[7] 杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[8] 杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[9] 刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[10] 陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[11] 余之刚,郑超. 乳腺癌多学科诊疗的现状、挑战与创新模式[J]. 山东大学学报 (医学版), 2025, 63(1): 1-9.
[12] 山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[13] 程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[14] 王敏, 李习平, 檀军, 邱梅, 侯泽宇, 田莹, 罗鸿莹, 范超文, 齐玲, 俞琦, 谢薇. 慢病毒载体介导Gag-Caspase-8诱导三阴性乳腺癌原代细胞凋亡及S期阻滞[J]. 山东大学学报 (医学版), 2025, 63(1): 25-34.
[15] 张洁,张芳芳,王靖楠,李泽宇,宋颖,李娜. circ_0000144在乳腺癌中的表达及其对乳腺癌细胞增殖、迁移和侵袭能力的影响[J]. 山东大学学报 (医学版), 2025, 63(1): 35-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发